Cargando…

The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival

BACKGROUND: Acute myeloid leukemia (AML) occurs frequently in the elderly, of whom the prognosis is dismal. Sarcopenia is a progressive and generalized skeletal muscle disorder associated with an increased possibility of adverse outcomes. This study aims to explore the prognostic value of sarcopenia...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Qian, Cui, Jialin, Liu, Wenjie, Li, Jianyong, Hong, Ming, Qian, Sixuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866858/
https://www.ncbi.nlm.nih.gov/pubmed/35223510
http://dx.doi.org/10.3389/fonc.2022.828939
_version_ 1784655924232716288
author Sun, Qian
Cui, Jialin
Liu, Wenjie
Li, Jianyong
Hong, Ming
Qian, Sixuan
author_facet Sun, Qian
Cui, Jialin
Liu, Wenjie
Li, Jianyong
Hong, Ming
Qian, Sixuan
author_sort Sun, Qian
collection PubMed
description BACKGROUND: Acute myeloid leukemia (AML) occurs frequently in the elderly, of whom the prognosis is dismal. Sarcopenia is a progressive and generalized skeletal muscle disorder associated with an increased possibility of adverse outcomes. This study aims to explore the prognostic value of sarcopenia in AML patients and develop a novel prognostic model. METHODS: A total of 227 AML patients were enrolled. Body composition was assessed by bioelectrical impedance analysis before treatment. Sarcopenia was diagnosed by low muscle quantity. Cox proportional hazard regression model were applied to verify prognostic variables for overall survival (OS) and disease-free survival (DFS). A novel prognostic model of nomogram was developed and validated by ‘R’. RESULTS: Forty-one (18.1%) patients were defined as sarcopenia. The median age of the sarcopenic group was significantly greater than the non-sarcopenic group (median 70 vs. 64 years, P = 0.001). Sarcopenic patients showed significantly less height (P = 0.002), weight (P <0.001), Body Mass Index (P <0.001), Fat Mass (P = 0.017), Fat-free Mass (P <0.001), Appendicular Skeletal Muscle Mass (P <0.001), Skeletal Muscle Index (P <0.001), Fat-free Mass Index (P <0.001), and hemoglobin level (P = 0.025) than the non-sarcopenic ones. Patients in the sarcopenic group also showed a statistically shorter OS and DFS (median OS: 13.7 vs. 55.6 months, P = 0.003; median DFS: 12.5 months vs. not reached, P = 0.026). ELN high risk [Hazard Ratio (HR): 1.904, 95% Confidence Interval (CI): 1.018–3.562, P = 0.044), sarcopenia (HR: 1.887, 95% CI: 1.071–3.324, P = 0.028), and reduced-intensity regimens (HR: 3.765, 95% CI: 1.092–12.980, P = 0.036) were independent predictors for OS in multivariate analysis. A nomogram for predicting OS was constructed using the above three factors. The c index, calibration plots and decision curve analyses (DCA) showed better discrimination, calibration, and net benefits of the nomogram than the ELN model. CONCLUSION: Sarcopenia was common and had an inferior prognosis in AML and needs more attention in clinical practice.
format Online
Article
Text
id pubmed-8866858
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88668582022-02-25 The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival Sun, Qian Cui, Jialin Liu, Wenjie Li, Jianyong Hong, Ming Qian, Sixuan Front Oncol Oncology BACKGROUND: Acute myeloid leukemia (AML) occurs frequently in the elderly, of whom the prognosis is dismal. Sarcopenia is a progressive and generalized skeletal muscle disorder associated with an increased possibility of adverse outcomes. This study aims to explore the prognostic value of sarcopenia in AML patients and develop a novel prognostic model. METHODS: A total of 227 AML patients were enrolled. Body composition was assessed by bioelectrical impedance analysis before treatment. Sarcopenia was diagnosed by low muscle quantity. Cox proportional hazard regression model were applied to verify prognostic variables for overall survival (OS) and disease-free survival (DFS). A novel prognostic model of nomogram was developed and validated by ‘R’. RESULTS: Forty-one (18.1%) patients were defined as sarcopenia. The median age of the sarcopenic group was significantly greater than the non-sarcopenic group (median 70 vs. 64 years, P = 0.001). Sarcopenic patients showed significantly less height (P = 0.002), weight (P <0.001), Body Mass Index (P <0.001), Fat Mass (P = 0.017), Fat-free Mass (P <0.001), Appendicular Skeletal Muscle Mass (P <0.001), Skeletal Muscle Index (P <0.001), Fat-free Mass Index (P <0.001), and hemoglobin level (P = 0.025) than the non-sarcopenic ones. Patients in the sarcopenic group also showed a statistically shorter OS and DFS (median OS: 13.7 vs. 55.6 months, P = 0.003; median DFS: 12.5 months vs. not reached, P = 0.026). ELN high risk [Hazard Ratio (HR): 1.904, 95% Confidence Interval (CI): 1.018–3.562, P = 0.044), sarcopenia (HR: 1.887, 95% CI: 1.071–3.324, P = 0.028), and reduced-intensity regimens (HR: 3.765, 95% CI: 1.092–12.980, P = 0.036) were independent predictors for OS in multivariate analysis. A nomogram for predicting OS was constructed using the above three factors. The c index, calibration plots and decision curve analyses (DCA) showed better discrimination, calibration, and net benefits of the nomogram than the ELN model. CONCLUSION: Sarcopenia was common and had an inferior prognosis in AML and needs more attention in clinical practice. Frontiers Media S.A. 2022-02-10 /pmc/articles/PMC8866858/ /pubmed/35223510 http://dx.doi.org/10.3389/fonc.2022.828939 Text en Copyright © 2022 Sun, Cui, Liu, Li, Hong and Qian https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Sun, Qian
Cui, Jialin
Liu, Wenjie
Li, Jianyong
Hong, Ming
Qian, Sixuan
The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival
title The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival
title_full The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival
title_fullStr The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival
title_full_unstemmed The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival
title_short The Prognostic Value of Sarcopenia in Acute Myeloid Leukemia Patients and the Development and Validation of a Novel Nomogram for Predicting Survival
title_sort prognostic value of sarcopenia in acute myeloid leukemia patients and the development and validation of a novel nomogram for predicting survival
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866858/
https://www.ncbi.nlm.nih.gov/pubmed/35223510
http://dx.doi.org/10.3389/fonc.2022.828939
work_keys_str_mv AT sunqian theprognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT cuijialin theprognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT liuwenjie theprognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT lijianyong theprognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT hongming theprognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT qiansixuan theprognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT sunqian prognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT cuijialin prognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT liuwenjie prognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT lijianyong prognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT hongming prognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival
AT qiansixuan prognosticvalueofsarcopeniainacutemyeloidleukemiapatientsandthedevelopmentandvalidationofanovelnomogramforpredictingsurvival